Why carry out this study?

Children with younger age and lower degree of myopia are more likely to experience rapid axial progression during orthokeratology (OK) or atropine monotreatment.

We conducted this study to assess whether there is an add-on effect of 0.01% atropine in OK wearers for children’s myopia control and if the effect is sustainable.

What was learned from the study?

We confirmed that axial elongation over 2 years might be distinctly suppressed by the combination of OK and 0.01% atropine, but the add-on effect of 0.01% atropine in OK wearers only occurred within 1.5 years of treatment.

We found that children of a younger age would benefit more from the OK lenses and 0.01% atropine combination therapy.